Ironwood Pharma (IRWD) Posts Q1 Loss of 38c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Aegis Maintains Ironwood Pharma (IRWD) at Buy; Still Positive on LINZESS Amid Slower Start
April 29, 2014 12:02 PM EDTAegis Capital reaffirms its Buy rating and $16 target price on Ironwood Pharmaceuticals (Nasdaq: IRWD) following the company's Q1 report. Ahead of the bell, Ironwood posted Q1 loss of $.38 per share with revenue of $14.6 million, versus consensus estimates looking for a loss of $.44 per share with revenue of $8.52 million.
Analyst Ram Selvaraju commented, On its earnings conference call,... More
